Home Blog Page 1129

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy

TAIPEI and SAN DIEGO, Dec. 29, 2025 /PRNewswire/ — Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. (TPEx: 6492, hereafter “Senhwa”), today announced another major milestone. The Company’s first-in-class investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the globally recognized antibody-drug conjugate (ADC), Trastuzumab Deruxtecan (Enhertu®), in a Phase 1b clinical trial. The study is designed for HER2-positive solid tumors and breast cancer patients, including those with HER2-low expression and metastatic breast cancer. Supported by the U.S. National Cancer Institute’s (NCI) NExT program, which funds multiple CX-5461 studies including combination strategies, Senhwa is positioning itself at the forefront of one of the most promising areas in oncology therapeutics, and this milestone marks CX-5461’s entry into the fast-growing ADC market.

World’s First G4 Stabilizer Meets Leading ADC

CX-5461 is the world’s first and most advanced G-quadruplex (G4) stabilizer in development. It has shown promising activity in early-phase trials for breast cancer and other solid tumors in study sponsored by SU2C-CCTG in Canada. Its combination with Enhertu® is expected to enhance treatment efficacy in HER2-low patients and offer new therapeutic possibilities.

Enhertu®, co-developed by AstraZeneca and Daiichi Sankyo, is the first HER2-directed ADC approved for HER2-low and HER2-ultralow metastatic breast cancer. This innovative drug uses a monoclonal antibody to precisely target tumor cells and deliver the chemotherapy payload Deruxtecan directly into the tumor, enabling highly effective cancer cell killing while minimizing harm to healthy cells.

Entering a High-Growth Market

The global ADC market is projected to grow at a CAGR of 28.4%, reaching approximately USD 47 billion by 2029. Analysts believe that Senhwa’s clinical development strategy combining CX-5461 and Enhertu® positions the company to directly tap into this high-growth and highly competitive oncology market.

Differentiated Advantage and Strategic Collaboration Potential

Although existing HER2-targeted therapies have transformed the treatment landscape for breast and gastric cancers, their efficacy in HER2-low solid tumors remains limited. Experts suggest that if CX-5461’s novel mechanism of action, when combined with ADC’s precise delivery platform, proves effective, it could break through current treatment barriers, expand indications to additional tumor types, and establish a clear competitive edge.

With global pharmaceutical companies racing into the ADC space, collaborations and licensing agreements have become mainstream. Should Senhwa’s combination therapy demonstrate strong clinical efficacy, it could attract strategic partnerships with major international pharma players, bringing in substantial licensing revenues and long-term collaboration opportunities.

Driving Long-Term Value Creation

Analysts further note that the successful advancement of this trial would significantly enhance Senhwa’s international visibility in oncology, elevate the company’s market valuation, and deliver sustainable long-term returns for investors and shareholders.

HER2 has been validated as a critical oncogenic driver across multiple tumor types. By leveraging the innovative combination of CX-5461 and Enhertu®, Senhwa aims to pioneer breakthrough therapies, capture a substantial share of the rapidly growing ADC market, and build a diverse oncology treatment platform. The company reiterated its commitment to strengthening its R&D pipeline, integrating next-generation ADC technologies with its proprietary drug candidates, and advancing toward its vision of becoming a leading Asia-based oncology innovator with a global footprint.

Senhwa Biosciences – CX-5461 NCI-NExT Program Clinical Trial Overview

No.

Study Title

Total Subjects

Primary Endpoints

Global Market Forecast

1

Pilot Study of Pidnarulex Pharmacodynamics
in Patients with Advanced Solid Tumors

Up to 40 subjects
HRD / Non-HRD (20 each)

Evaluation of RAD51 response and DNA damage response

2024: USD 362.2B
CAGR: 20%
2032: USD 1,557.4B

2

Phase 1b/2 Trial of Pidnarulex
in MYC Aberrant Lymphoma

Up to 50 subjects
Phase 1b: 36
Phase 2: 8–14

1. Safety and DLT evaluation on CX-5461
2. RP2D for on CX-5461
3. ORR
4. CX-5461 PK
5. Effect on MYC-aberrant lymphoma gene expression

2024: USD 4.9B
CAGR: 5.79%
2035: USD 8.9B

3

A Phase 1 and Randomized Phase 2 Trial
of Pidnarulex (CX-5461) and Cemiplimab (REGN2810)
in Refractory Microsatellite Stable Colorectal Cancer

Up to 86 subjects
Phase 1: 18
Phase 2: 68

1. CX-5461 RP2D combined with PD-1 inhibitor
2. Safety & tolerability for CX-5461 monotherapy & combination
3. PFS in refractory MSS CRC with liver metastases for CX-5461 monotherapy & combination

2025: USD 58.0B
CAGR: 15%
2035: > USD 250.0B

4

Phase 1b study
of Pidnarulex and Trastuzumab Deruxtecan
in patients with HER2 expressing Solid Tumors

Up to 36 subjects

1. MTD & RP2D determination for combination of CX-5461 and Trastuzumab Deruxtecan
2. Safety and tolerability in HER2-low and HR+ HER2-ultra-low breast cancer  for combination of CX-5461 and Trastuzumab Deruxtecan

2023: USD 10.8B
CAGR: 28.4%
2029: USD 47.0B

 

Notes

✽ All above clinical trial costs are funded by the U.S. National Cancer Institute (NCI)

✽ Global market forecasts reference: Data Bridge, BioSpace, IQVIA, BCC Research

✽ Source: Provided by Senhwa Biosciences

 

Sixth Jiangbeizui New Financial Conference Opens in Chongqing’s Liangjiang New Area

CHONGQING, China, Dec. 29, 2025 /PRNewswire/ — A news report from Xinhua Finance:

The sixth Jiangbeizui New Financial Conference was held in Chongqing’s Liangjiang New Area on December 28. Themed “New Finance, New Opportunities: Intelligent Integration for Inclusive and Efficient Finance — Fostering the Development of a Western Financial Center,” the event brought together more than 500 industry experts and business representatives from China and abroad.

(PRNewsfoto/)
(PRNewsfoto/)

In recent years, Chongqing has implemented the “Intelligent Integration for Inclusive and Efficient Finance” initiative to strengthen financial support for economic development, while Liangjiang New Area has drawn on the concentration of financial institutions and professionals in Jiangbeizui to support the establishment of the core functional zone of the Western Financial Center. As a result, Jiangbeizui’s financial sector has steadily grown in overall strength and regional influence, with a notable increase in its ability to serve the real economy.

At the conference, Liangjiang New Area unveiled its private equity fund cluster. Since the beginning of the year, the area has introduced 12 private equity funds focused on advanced manufacturing, semiconductors, aerospace and space-based information technologies, and technology commercialization, with a total committed capital exceeding RMB 10 billion.

The conference also featured the signing ceremony for the “Joining Forces for Quality-Driven Production: Building a New Sci-Tech Finance Ecosystem” program, which is intended to collaboratively establish a new ecosystem for science and technology finance. In addition, the Jiangbeizui Financial Service Center of the New Land-Sea Corridor was formally inaugurated, providing integrated one-stop financial services and serving as a showcase for the effectiveness of financial services supporting the corridor’s development.

During the plenary session, speeches were delivered by prominent figures including Lin Yifu, Dean of the Institute of New Structural Economics and Honorary Dean of the National School of Development at Peking University, and Ma Weihua, Chairman of Menglang Sustainable Digital Technology and former President of China Merchants Bank.

Liangjiang New Area serves as the primary platform and main hub for Chongqing to implement national initiatives, enhance productivity, and drive the growth of new and emerging industries. It also acts as the central hub for Chongqing’s developing role as a Western Financial Center. With a solid industrial foundation, a well-established financial service system, the combined effect of multiple national initiatives, and a favorable financial policy environment, Liangjiang New Area offers broad opportunities for business growth.

A New Year’s Passage Through Shaanxi, Where History and Daily Life Converge

XI’AN, China, Dec. 26, 2025 /PRNewswire/ — This article is distributed by the Shaanxi Provincial Department of Culture and Tourism. As 2026 approaches and year-end reflection sets in, travelers seeking a New Year’s destination made easier to reach under China’s 240-hour visa-free transit policy will find an inviting proposition in Shaanxi.

This is a place where the past feels tangible and flavors feel enduring, with traditions coming alive with unusual intimacy during the New Year season.

For a journey centered on culture, start at Baoji’s Famen Temple. History here is not preserved behind glass; it persists through living ritual, architecture, and a sense of quiet continuity. At midnight on New Year’s Eve, the temple bell is rung 108 times, marking a centuries-old rite that symbolizes the release of the old year and the welcome of the new.

Naturally, any trip to Shaanxi is also defined by its deeply rooted culinary heritage.

In Tongchuan, flavors are straightforward, hearty and deeply satisfying. Yaozhou noodles, hand-crafted to a unique honeycomb texture, offer a pleasing chew, served either with a savory meat sauce or a clear, flavorful broth. Hand-sliced noodles, with their signature spicy and tingling profile, are smooth and resilient — the sort of dish that lingers in memory and invites return. Near Yaowang Mountain, Sun Simiao medicinal cuisine, prepared with local herbs, focuses on wholesome nourishment rather than complexity, delivering a plainspoken, restorative sense of sustenance.

During the Lunar New Year period, the old streets of Yulin pulse with energy and sound. The air carries melodies of Northern Shaanxi folk songs, the spirited movements of yangko dances, and a rolling sequence of local Yulin ditties. These are not staged shows but unrehearsed celebrations spilling into the lanes and alleys, carrying the vigorous spirit of the Loess Plateau — lively, genuine and marked by an easy warmth.

Then, there is Xi’an.

This time, look beyond the city walls and the Terracotta Army. Enter Huaqing Palace and settle into the misty embrace of its historic hot springs. These same waters that once cradled the legendary Yang Guifei now offer warmth, collapsing imperial history into an intimate, bodily experience.

Travelers can rush through crowded cities, or they can choose to slow down in Shaanxi — greeting dawn at an ancient temple, savoring midday street food, and listening to folk songs as evening falls. Here, history is no longer remote; it appears unannounced and stays with you in ways that feel personal rather than performative.

With visa-free entry making the region easier to reach, the journey to Shaanxi begins now. Each city tells its own story, threading the joy and warmth of the New Year through the layered texture of its past.

 

Agoda Releases Ranking of Japan’s Most Popular Domestic Winter Travel Destinations

  • Regional Events in February Drive Travel Demand Following Tokyo and Osaka
  • Seasonal events such as Fukuoka’s “Path of Light,” Sapporo’s “Sapporo Snow Festival,” and Okinawa’s “Cherry Blossom Festival” contribute to rising interest in regional cities

TOKYO, Dec. 29, 2025 /PRNewswire/ — Digital travel platform Agoda, operated by Agoda Company Pte. Ltd. (Headquartered in Singapore, CEO: Omri Morgenshtern), today announced the top five domestic destinations in Japan gaining booking momentum this winter (December 2025February 2026), based on search data from Japanese travelers.

In the 2025 winter travel search trends, Tokyo and Osaka continued to lead the ranking, maintaining the top two positions from the previous year. At the same time, regional cities again demonstrated strong appeal, with Fukuoka, Sapporo, and Okinawa Main Island all placing in the top five. The data suggests that seasonal winter events have significantly contributed to increased search interest in these cities.

Domestic Winter Travel Destination Ranking (Dec–Feb)

Ranking

2024

2025

1

Tokyo

Tokyo

2

Osaka

Osaka

3

Fukuoka

Fukuoka

4

Kyoto

Sapporo

5

Okinawa Main Island

Okinawa Main Island

 

February Regional Events Fuel Search Growth

A notable trend revealed in the search data is the strong influence of February seasonal events in boosting interest in regional destinations.

  • Fukuoka: Miyajidake Shrine “Path of Light” (February) – A mystical sunset phenomenon visible only twice a year, the “Path of Light” has become popular on social media, contributing to increased February travel searches.
  • Sapporo: Sapporo Snow Festival (Early February) – Japan’s largest winter event, attracting visitors from Japan and abroad. With its ice sculptures, illuminated displays, and food festivals, Sapporo remains a leading city for winter travel demand.
  • Okinawa Main Island: Cherry Blossom Festival (Early February) – Okinawa is the first place in Japan where cherry blossoms bloom each year. The island’s warm climate combined with early-blooming sakura maintains its steady popularity as a winter getaway.

Overall, the data clearly indicates that seasonal events concentrated in February are a major driver of domestic winter travel demand.

Tadashi Ikai, Senior Country Director, Agoda International Japan, shared: “Agoda’s latest search data shows that, in addition to major metropolitan areas such as Tokyo and Osaka, regional cities hosting rich seasonal events in February are also receiving a high volume of searches. Experiences unique to winter – such as Fukuoka’s Path of Light, Sapporo’s Sapporo Snow Festival, and Okinawa Main Island’s Cherry Blossom Festival, are capturing travelers’ interest and strongly driving demand for winter travel. At Agoda, we remain committed to helping travelers fully enjoy these diverse winter experiences. By continuing to offer a wide range of domestic options and a seamless booking experience, we aim to make every journey more fulfilling and memorable for our users.”

Travelers can seamlessly search and book more than 6 million accommodations, 130,000+ flight routes, and 300,000+ activities through Agoda’s platform. Attractive accommodation deals can be easily found via the Agoda mobile app or official website (Agoda.com).

Tanoto Foundation Convened Global and National Leaders to Strengthen the Early Childhood Education and Development (ECED) Ecosystem at the 2025 International Symposium on ECED

SINGAPORE – Media OutReach Newswire – 29 December 2025 – Tanoto Foundation convened government leaders, international organisations, researchers, and civil society at the 2025 International Symposium on Early Childhood Education and Development (ECED), in Jakarta under the theme “ECED Ecosystem Synergy in Promoting the Best Start in Life.

The symposium comes at a critical moment, as shared challenges across health, nutrition, education, and caregiving continue to shape early childhood development outcomes in Indonesia and globally, where many young children continue to face barriers to healthy development, from gaps in nutrition and care to limited access to quality early learning.

These challenges highlight the need for closer coordination across health, education, parenting, and social protection to ensure children receive holistic and equitable support from the earliest years.

Without strong cross-sector collaboration, Indonesia risks losing momentum in building its human capital and realising its demographic dividend towards Indonesia Emas 2045.

In partnership with key government ministries and cross-sector organisations, Tanoto Foundation convened the symposium as a platform to align policy, practice, and evidence across sectors, bringing together representatives from central and local government, international organisations, academia, civil society, and philanthropy.

The symposium featured two main discussion tracks focused on health and education, and parenting in early childhood.

The morning segment, “Synergising Health and Education for ECED”, focused on integrating health, nutrition, and early learning services, highlighting innovations in growth and development monitoring, nutrition interventions, and early stimulation within primary service systems.

The afternoon session, “Parenting and Early Learning”, placed families and caregivers at the centre of the ECED ecosystem, exploring responsive caregiving, interaction-based learning, and policy support to strengthen parents’ capacity to nurture children’s development.

Indonesian Minister of Health Budi Gunadi Sadikin officially opened the symposium, emphasising the decisive importance of early childhood for national development.

“The age of 0 to 5 years is a highly decisive phase in determining whether a person will grow into a healthy, intelligent adult who can contribute to the nation, including to increase per capita income,” the Minister said.

“If we do not act quickly, we risk missing Indonesia’s demographic dividend. This is our responsibility to our children.”

The Government of Indonesia has reaffirmed early childhood development as a national priority through the Long-Term National Development Plan 2025 to 2045 and the Medium-Term National Development Plan 2025 to 2029, with Holistic and Integrated Early Childhood Development (PAUD-HI) designated as a key performance indicator.

Opening the afternoon session, Indonesian Minister of Women Empowerment and Child Protection, Arifatul Choiri Fauzi, highlighted the symposium’s contribution to policy strengthening.

“This forum brings together strategic cross sector perspectives. We encourage the resulting recommendations to be used to strengthen policies, regulations, and service innovations for early childhood development,” she said.

Indonesian Deputy Minister of Higher Education, Science, and Technology, Prof. Stella Christie, underscored the importance of science-based parenting and high-quality interaction.

“Caregiving with optimal interaction between children and caregivers has the greatest potential to maximise child development,” she said. “No technology, including artificial intelligence, can replace the power of human interaction.”

She added that children learn through curiosity, imitation, and everyday experiences, making responsive and evidence-based parenting critical for brain development and lifelong learning.

CEO of Tanoto Foundation Benny Lee reaffirmed the Foundation’s long-term commitment to early childhood development as a cornerstone of human potential.

“The early years are when the foundations of brain development, health, and character are formed,” Benny said.

“This is not the work of one institution. It requires a truly supportive ecosystem built through collaboration among government, civil society, academia, and philanthropy.”

He emphasised that Tanoto Foundation, founded by Sukanto Tanoto, Founder and Chairman of Royal Golden Eagle (RGE), views early childhood development as a primary investment, where collective action can deliver lasting and sustainable impact. “This symposium is about ensuring that every child receives the strongest possible start in life, every parent receives the support they need, and every sector moves forward together,” he said.

The symposium brought together up to 200 participants, with speakers from government, development organisations, academia, research institutions, and philanthropy.
Hashtag: #RGE #TanotoFoundation #Philanthropy #Indonesia #ECED #EarlyChildhood #Healthcare

The issuer is solely responsible for the content of this announcement.

About Tanoto Foundation

At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realise his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes.

Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore

SINGAPORE, Dec. 29, 2025 /PRNewswire/ — Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic, Assure Family Clinic Woodlands. This expansion marks the next phase in the Group’s mission to make quality and comprehensive healthcare more accessible to families and individuals.

The newly opened Assure Family Clinic Woodlands extends Assure Healthcare Holdings’ reach to northern Singapore.
The newly opened Assure Family Clinic Woodlands extends Assure Healthcare Holdings’ reach to northern Singapore.

Located in the heart of Woodlands at 132 Marsiling Rise, the new clinic extends Assure Healthcare Holdings’ footprint beyond its first location in Bukit Merah. The clinic will provide residents in northern Singapore with convenient access to general consultations, chronic disease management, vaccinations, preventive health screenings, and minor procedures.

“The launch of the Assure Family Clinic in Woodlands marks an important milestone in our growth journey,” said Dr Joanne Koay, Chief Medical Officer of Assure Healthcare Holdings. “Our goal is to bring compassionate, reliable care closer to the communities we serve, giving families peace of mind knowing that accessible healthcare is always within reach.”

Leading the Woodlands clinic is Dr Vikneswaran V. Paranjothy, a General Practitioner with specialised training in occupational medicine, dermatology, aesthetics, and andrology. With extensive experience in workplace health, preventive care, and minor procedures, Dr Vik takes a holistic and patient-centred approach to serving the community.

“Healthcare is a cornerstone of SingWealth Holdings’ vision to provide holistic solutions across health, wealth, and legacy planning,” added Jeffrey Chow, Executive Director and Group CEO of SingWealth Holdings. “The expansion reflects our strong commitment to supporting the well-being of Woodlands’ residents, as well as our SingWealth’s clients and their families at every stage of life. This includes critical planning tools such as the Advance Medical Directive, which empower individuals to make informed decisions about their future care and uphold their personal values with dignity.”

For more information about the clinic’s services or to book an appointment, please visit assureclinic.sg.

About Assure Healthcare Holdings

Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, is dedicated to delivering accessible, patient-centered care through a growing network of medical practices. Its comprehensive suite of services includes General Practitioner (GP) consultations, preventive medical care, aesthetic treatments, and Advance Medical Directive (AMD) support.

With a commitment to enhancing community healthcare, Assure Healthcare Holdings provides quality care and trusted medical guidance to support individuals and families at every stage of life.

For more information, visit assureclinic.sg

About SingWealth Holdings

SingWealth Holdings is a dynamic holding company with a strategic presence across Singapore, Thailand, Malaysia, China, and Hong Kong. Through its subsidiaries, it delivers comprehensive financial advisory, insurance brokerage, and estate planning solutions tailored to the evolving needs of individuals and businesses.

Its financial services portfolio comprises PFPFA Pte Ltd (Singapore), PFPFA HK Ltd (Hong Kong), and PFPFA (Malaysia) Sdn Bhd, providing trusted financial expertise and strategic advisory solutions to clients in their respective markets.

SingWealth Holdings also supports PFP Legacy entities across the region, catering to the needs of emerging affluent clients with wills and trust services in Singapore, Thailand, Malaysia, Hong Kong, and Shanghai. These services are designed to safeguard wealth and ensure smooth succession planning for individuals and families.

In Singapore, SingWealth Holdings operates Assure Healthcare Holdings, a healthcare brand committed to accessible, patient-centered care. Assure Healthcare offers general practitioner services, preventive medical care, aesthetic treatments, and Advance Medical Directive (AMD) support.

Driven by innovation and excellence, SingWealth Holdings continues to empower communities across Asia with financial stability and enhanced well-being.

For more information, visit https://singwealthholdings.com.

 

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. (“Lannacheng”). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).

Compared with conventional radiotherapy, RDCs utilize tumor antigen–specific ligands to deliver radionuclides directly to tumor lesions for targeted radiotherapy, thereby effectively reducing damage to surrounding healthy tissues. In contrast to antibody–drug conjugates (ADCs), the radionuclides in RDCs can also exert cytotoxic effects on neighboring tumor cells and the tumor microenvironment, even if those cells do not express the target antigen. This mechanism offers a potential advantage in overcoming tumor heterogeneity and drug resistance. In addition, this technology holds the potential to achieve theranostics—integrating both diagnosis and treatment.

With its advanced technology platforms and deep expertise, Harbour BioMed has built a solid foundation in antibody discovery and development. The company’s proprietary Harbour Mice® platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanization. The HCAb technology, in particular, produces unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapeutics. In the development of RDCs, fully human antibodies—characterized by low immunogenicity, superior tissue penetration, and high specificity and stability—can significantly enhance the efficiency of targeted delivery, thereby improving therapeutic efficacy while effectively reducing drug-related toxicity and side effects.

Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of integrated theranostic radiopharmaceuticals for oncology. The company’s R&D engine, enhanced by its proprietary pharmacokinetic optimization and dual-targeting drug development platforms, combines target validation, radioisotope selection, and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates. Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable, and rapidly innovating radiopharmaceutical pipeline.

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are very pleased to establish a long-term strategic collaboration with Lannacheng to jointly advance the development of next-generation RDCs. Harbour BioMed is committed to providing efficient and highly differentiated antibody solutions for innovative therapies through our globally leading Harbour Mice® fully human antibody platform. This collaboration will deeply integrate Harbour BioMed’s expertise in antibody discovery with Lannacheng’s strengths in radiopharmaceutical R&D and commercialization, accelerating the development of more precise, effective and safe cancer therapies and bringing new hope to patients worldwide.”

Wu Xiaoming, General Manager of Lannacheng, stated: “We are delighted to establish a long-term strategic collaboration with Harbour BioMed to jointly advance the R&D and translation of next-generation radiopharmaceuticals. Lannacheng is committed to leveraging our systematic radiopharmaceutical technology platform, comprehensive industrial capabilities, and global collaboration network to provide efficient, innovative, and differentiated integrated solutions for tumor diagnosis and treatment. This collaboration will fully combine Lannacheng’s strengths in radiopharmaceutical R&D and commercialization and Harbour BioMed’s deep expertise in antibody discovery. Together, we aim to accelerate the development of more precise, effective, and safe cancer treatment therapies, bringing new hope to patients worldwide.”

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICA™) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICA™ with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

About Yantai Lannacheng Biotechnology Co., Ltd.

Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of integrated theranostic radiopharmaceuticals for oncology. The company’s R&D engine, enhanced by its proprietary pharmacokinetic optimization and dual-targeting drug development platforms, combines target validation, radioisotope selection, and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates. Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable, and rapidly innovating radiopharmaceutical pipeline.

Laos, Vietnam Set 2026 Agenda for Border Protection, Trade

Laos, Vietnam Set 2026 Agenda for Border Protection, Trade
Lao Minister of Public Security General Somphanh Phengkhammy (right) and his Vietnamese counterpart Nguyen Van Son, head of Vietnam’s Border Defense Department (left), shake hands (photo credit: Lao Security News)

Laos and Vietnam have set key areas of cooperation for 2026 in border management and cross-border activities, following the 34th annual meeting between the two countries’ border delegations in Vientiane from 25 to 27 December.